Association of ERCC1 and BRCA1 Expression with Clinical and Pathological Features and Sensitivity to Platinum-containing Adjuvant Chemotherapy in Patients with Ovarian Epithelial Carcinoma
10.3870/yydb.2014.06.016
- VernacularTitle:ERCC1和BRCA1表达与原发性上皮性卵巢癌患者临床因素及铂类化疗敏感性的研究
- Author:
Pei DU
;
Yifeng WANG
;
Xiaowei ZHANG
;
Liquan CHEN
;
Guoqin CHEN
- Publication Type:Journal Article
- Keywords:
Cancer drug resistance;
Tumor,ovarian;
ERCCl;
BRCA1
- From:
Herald of Medicine
2014;(6):747-751
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the association of ERCC1 and BRCA1 gene expression with clinical features and sensitivity to platinum-containing chemotherapy in patients with ovarian epithelial carcinoma. Methods Primary ovarian epithelial carcinoma tissues were harvested from 48 patients receiving staging surgery or cytoreductive surgery. Expression of ERCC1 and BRCA1 in the tumor samples was detected by immunohistochemistry. Results ERCC1 expression was correlated with clinical stage(P﹤0. 05)but not with age,pathological type or degree of differentiation(P﹥0. 05). BRCA1 expression was not correlated with any of the clinicopathological features(P﹥0. 05);ERCC1 expression was significantly higher in drug-resistant tissues than in drug-sensitive samples(P﹤0. 05);The expression of ERCC1 and BRCA1 was positive in 89. 58%and 25. 00%of the samples,respectively. Conclusion ERCC1 gene expression is correlated with clinical stage but not with age,pathological type or degree of differentiation. BRCA1 gene expression is not correlated with clinicopathological features. ERCC1 has high positive expression in epithelial ovarian cancer and is correlated with sensitivity of platinum-containing adjuvant chemotherapy.
